AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review. Fukushima J Med Sci. 2018;64(2):46–53. doi:10.5387/fms.2018-0930058598
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, Phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627–637. doi:10.1016/S1470-2045(13)70136-023623280
   PubMed Web of Science ®Google Scholar
• Vicente-Dueñas C, Hauer J, Cobaleda C, Borkhardt A, Sánchez-García I. Epigenetic priming in cancer initiation. Trends Cancer. 2018;4(6):408–417. doi:10.1016/j.trecan.2018.04.00729860985
   PubMed Web of Science ®Google Scholar
• Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol. 2018;98:65–74. doi:10.1016/j.biocel.2018.03.00429535070
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, Spartalis E, Pawlik TM. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surg Oncol. 2018;27(4):611–618. doi:10.1016/j.suronc.2018.07.01530449480
   PubMed Web of Science ®Google Scholar
• Mishra VK, Wegwitz F, Kosinsky RL, et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017;45(11):6334–6349. doi:10.1093/nar/gkx21228369619
   PubMed Web of Science ®Google Scholar
• Bao L, Diao H, Dong N, et al. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol. 2016;32(6):469–482. doi:10.1007/s10565-016-9347-827423454
   PubMed Web of Science ®Google Scholar
• Wahaib K, Beggs AE, Campbell H, Kodali L, Ford PD. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Am J Health Syst Pharm. 2016;73(7):441–450. doi:10.2146/ajhp15048727001985
   PubMed Web of Science ®Google Scholar
• Zeng LS, Yang XZ, Wen YF, et al. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging. 2016;8(6):1236–1249. doi:10.18632/aging.10098027295551
   PubMedGoogle Scholar
• Li S, Wang F, Qu Y, et al. HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. Oncol Lett. 2017;13(1):403–409. doi:10.3892/ol.2016.543628123574
   PubMed Web of Science ®Google Scholar
• Song M, He G, Wang Y, Pang X, Zhang B. Lentivirus-mediated knockdown of HDAC1 uncovers its role in esophageal cancer metastasis and chemosensitivity. J Cancer. 2016;7(12):1694–1700. doi:10.7150/jca.1508627698906
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wang WH, Wu WY, et al. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways. PLoS One. 2017;12(8):e0183368. doi:10.1371/journal.pone.018336828829799
   PubMed Web of Science ®Google Scholar
• Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005;48(17):5530–5535. doi:10.1021/jm050374916107152
   PubMed Web of Science ®Google Scholar
• Li DR, Zhang H, Peek E, et al. Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer. J Urol. 2015;194(2):547–555. doi:10.1016/j.juro.2015.02.291825748177
   PubMed Web of Science ®Google Scholar
• Guzman ML, Yang N, Sharma KK, et al. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther. 2014;13(8):1979–1990. doi:10.1158/1535-7163.MCT-13-096324934933
   PubMed Web of Science ®Google Scholar
• Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia. 2009;11(6):552–563. doi:10.1593/neo.0920419484144
   PubMed Web of Science ®Google Scholar
• Zhong L, Fu XY, Zou C, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. Int J Cancer. 2014;135(12):2972–2983. doi:10.1002/ijc.2894424789676
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637–656. doi:10.1016/j.molonc.2012.09.00323141799
   PubMed Web of Science ®Google Scholar
• Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J. 2016;52(1):1–11. doi:10.4068/cmj.2016.52.1.126865995
   PubMedGoogle Scholar
• Lu Q, Yang YT, Chen CS, et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004;47(2):467–474. doi:10.1021/jm030365514711316
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27. doi:10.1016/j.cell.2012.06.01322770212
   PubMed Web of Science ®Google Scholar
• Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int. 2012;2012:1–10. doi:10.1155/2012/184154
   Web of Science ®Google Scholar
• Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414–1438. doi:10.3390/ijms18071414
   PubMed Web of Science ®Google Scholar